Betta Pharmaceuticals Co (300558.SZ) Stock Price
Betta Pharmaceuticals Co Price
Revenue has compounded at 33.6% per year over the past 14 years to 3.61 B CNY. Earnings per share have grown at 22.6% per year over the last 14 years. Betta Pharmaceuticals Co's net margin stands at 8.5%, down from 17.1% several years earlier. Betta Pharmaceuticals Co currently offers a dividend yield of about 0.41%. The payout ratio is around 28% of earnings. The dividend has grown at 1.3% per year over the past 8 years. Analysts set a median price target of 65.07 CNY, implying 34.8% above the current price. Of 9 analysts, 6 rate the stock a buy — an overall Buy consensus.
Betta Pharmaceuticals Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Betta Pharmaceuticals Co business model & stock analysis
Frequently asked questions about Betta Pharmaceuticals Co
Analysts currently set an average price target of 65.07 CNY for the Betta Pharmaceuticals Co stock (median: 65.07 CNY), implying +34.8 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Betta Pharmaceuticals Co stock: 6 recommend buying, 2 holding and 1 selling. For 2026, analysts expect Betta Pharmaceuticals Co to generate revenue of 4.10 B CNY and earnings per share of 1.37 CNY.
Converted at the current exchange rate, the Betta Pharmaceuticals Co share trades at 6.46 EUR (48.27 CNY).
The Betta Pharmaceuticals Co share (300558.SZ) is listed on 1 stock exchanges, including: Shenzhen (300558.SZ).
The expected revenue of Betta Pharmaceuticals Co is 4.10 B CNY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Betta Pharmaceuticals Co is 579.60 M CNY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Betta Pharmaceuticals Co is currently 35.31. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Betta Pharmaceuticals Co stock.
The price-to-sales ratio (P/S) of Betta Pharmaceuticals Co is currently 4.99. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Betta Pharmaceuticals Co stock.
The Eulerpool Quality Score for Betta Pharmaceuticals Co is 6/10.
The ISIN of Betta Pharmaceuticals Co is CNE100002DD9. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Betta Pharmaceuticals Co is 300558.SZ. The ticker symbol is used to trade Betta Pharmaceuticals Co shares on the stock exchange.
Betta Pharmaceuticals Co stock
Betta Pharmaceuticals Co Peer Group
Betta Pharmaceuticals Co Ticker
Betta Pharmaceuticals Co FIGI
All fundamentals and in-depth analysis of Betta Pharmaceuticals Co
Our stock analysis for Betta Pharmaceuticals Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Betta Pharmaceuticals Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.